×
-0.00896592946802143 -0.00896592946802143 -0.00298864315600722 -0.0107591153616258 -0.0281888822474596 -0.0107591153616258 -0.0221159593544531 -0.00119545726240284
Stockreport

Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society

DECIPHERA PHARMACEUTICALS (DCPH)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: deciphera.com/investor-relations
PDF - Data Support the Selection of the Recommended Daily Dose of 150 mg - - Durable Disease Control Rates in Heavily Pretreated GIST Patients and Reductions in KIT Mutations Supporting pan-KIT Activity of DCC-2618 Across Spectrum of Exons - - DCC-2618 Continues to Demonstrate Good Tolerability with Over 120 Patients Dosed to Date - WALTHAM, Mass., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced the presentation of data analysis from its ongoing Phase 1 clinical trial of DCC-2618, the Company’s pan-KIT and PDGFRa inhibitor. The analysis and update was presented at the Annual Meeting of The Connective Tissue Oncology Society (CTOS) on November 10, 2017, in Maui, HI, USA. The presentation reviews data from the same trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in September 2017, and provides pharm [Read more]

IMPACT SNAPSHOT EVENT TIME: DCPH
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS